Common menu bar links
Breadcrumb Trail
ARCHIVED - RPP 2007-2008
Health Canada
This page has been archived.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Section 3: Supplementary Information
The Health Portfolio
BranchHealth Canada also contributes grants and contributions to several health organizations such as Infoway, Canadian Institute for Health Information and Canadian Health Services Research Foundations.
* All of Health Canada's program activities contribute to the Government of Canada's "Healthy Canadians" outcome.
Table 1
|
Departmental Planned Spending and Full-Time Equivalents |
||||
|---|---|---|---|---|
| ($ millions) | Forecast Spending 2006-2007 (1) |
Planned Spending 2007-2008 |
Planned Spending 2008-2009 |
Planned Spending 2009-2010 |
| Health Policy, Planning and Information | 288.6 | 263.7 | 259.8 | 254.7 |
| Health Products and Food | 303.2 | 298.4 | 283.5 | 283.5 |
| Healthy Environments and Consumer Safety | 306.1 | 349.2 | 305.0 | 305.8 |
| Pest Control Product Regulation | 58.7 | 57.8 | 53.5 | 53.2 |
| First Nations and Inuit Health | 2,087.9 | 2,128.5 | 2,140.4 | 2,175.9 |
| Budgetary Main Estimates (gross) | 3,044.5 | 3,097.6 | 3,042.2 | 3,073.1 |
| Less: Respendable Revenues | 69.1 | 69.3 | 69.6 | 69.6 |
| Total Main Estimates | 2,975.4 | 3,028.3 | 2,972.6 | 3,003.5 |
| Adjustments : (2) | ||||
| Supplementary Estimates: | ||||
| Operating budget carry forward (horizontal item) | 81.1 | |||
| Additional funding for the Non-Insured Health Benefits program for First Nations and Inuit to address cash pressures associated with the higher costs of drugs and dental care, as well as the increased costs of transporation to access medical services | 30.0 | |||
| Funding to address workload and cost pressures in four of Health Canada's core business areas, namely, the Pesticides Regulatory Program ($1,402), the Natural Health Products Program ($7,367), the Public Service Health Program ($5,560) and Litigationmanagement ($9,233) | 23.6 | |||
| Funding to implement the Canadian Strategy for Cancer Control (horizontal item) | 3.8 | |||
| Transfer from the Public Health Agency of Canada - To adjust for the allocation of resources following the transfer of the control and supervision of the Population and Public Health Branch | 2.2 | |||
| Funding for the delivery of federal programs and services, including health, to the O-Pipon-Na-Piwin Cree Nation (horizontal item) | 1.5 | |||
| Transfer from the Public Health Agency of Canada - Forgovernment advertising programs | 1.5 | |||
| Funding to improve the capacity to detect and the readiness to respond to a potential avian or pandemic influenza outbreak including emergency preparedness, research, antiviral stockpiling and rapid vaccine development technology (horizontal item) | 1.3 | |||
| Transfer from the Public Health Agency of Canada - To implement the Canadian Strategy for Cancer Control (horizontal item) | 0.7 | |||
| Transfer from Industry Canada - To undertake projects related to the development and application of biotechnology (CanadianBiotechnology Strategy) (horizontal item) | 0.3 | |||
| Funding related to the assessment, management and remediation of federal contaminated sites (horizontal item) | 0.2 | |||
| Transfer from the Public Health Agency of Canada - To conduct reviews of the ethics of all Public Health Agency of Canada research involving human subjects | 0.2 | |||
| Transfer from Canadian Heritage - For the development of Official Language Minority Communities (Interdepartmental Partnership with the Official Language Communities) (horizontal item) | 0.2 | |||
| Transfer to the Public Health Agency of Canada - To support the Canadian Health Services Research Foundation's Community Health Nursing Study | -0.1 | |||
| Transfer to Foreign Affairs and International Trade - For the payment of assessed contributions representing Canada's membership in the Rotterdam Convention on the Prior Informed Consent for Certain Hazardous Chemicals and Pesticides in International Trade and in the Stockholm Convention on Persistent Organic Pollutants | -0.1 | |||
| Transfer to the Canadian Institutes of Health Research - To fund health services and health population research relevant to the surveillance of diabetes | -0.2 | |||
| Transfer to Indian Affairs and Northern Development - To provide for a grant to the Sechelt Indian Band pursuant to the Sechelt Indian Band Self-Government Act | -0.3 | |||
| Transfer to the Public Health Agency of Canada - To continue the Government's plan to establish core genomics research and development capacity | -1.4 | |||
| Less: Spending authorities available | -27.4 | |||
| Other adjustments: | ||||
| Collective Agreements | 19.2 | |||
| Internal Audit - Readiness Assessment (TB Vote 10) | 0.1 | |||
| Internal Audit - Implementation of the Internal Audit Policy (TB Vote 10) | 0.3 | 1.0 | ||
| 2005 Expenditure Review Committee Savings - Procurement | -4.6 | |||
| 2006 Expenditure Restraint | -23.0 | |||
| Funding for Indian Residential Schools Resolution Health Support Program | 7.5 | 14.0 | 18.9 | |
| Funding for the Genomics Research and Development Initiative, under the auspicies of the Canadian Biotechnology Strategy | 4.0 | 4.0 | ||
| Funding for the Winter Olympics | 0.6 | 2.0 | ||
| Adjustment of the accommodation costs for the Canadian Strategy for Cancer Control | -0.1 | -0.1 | -0.1 | |
| Less: Spending authorities available | -7.3 | |||
| Total Adjustments | 101.9 | 8.4 | 18.4 | 24.8 |
| Total Planned Spending (3) | 3,077.3 | 3,036.7 | 2,991.0 | 3,028.3 |
| Less: Non-respendable Revenue | 8.9 | 8.9 | 8.9 | 8.9 |
| Plus: Cost of services received without charge (4) | 81.7 | 81.6 | 81.8 | 80.6 |
| Total Departmental Spending | 3,150.1 | 3,109.4 | 3,063.9 | 3,100.0 |
| Full-Time equivalents (5) | 8,714 | 8,825 | 8,681 | 8,689 |
| (1) Reflects the best forecast of total net planned spending to the end of the fiscal year. (2) Adjustments reflect Supplementary Estimates for 2006-2007 and future year approvals not reflected in the 2007-2008 Main Estimates. (3) Refer to Section 2 for an explanation by program activity of year-over-year fluctuations. (4) Includes the following services received without charge: accommodation charges (Public Works and Government Services Canada); Contributions covering employers' share of employees' insurance premiums and expenditures (Treasury Board Secretariat); Workers' Compensation (Human Resources and Skills Development Canada); and Legal Services (Department of Justice Canada). (5) Full-time equivalents reflect the human resources that the Department uses to deliver its programs and services. This number is based on a calculation that considers full-time, term, casual employment, and other factors such as job sharing. |
||||
Table 2
| Voted and Statutory Items listed in Main Estimates (in millions of dollars) | |||
|---|---|---|---|
| Vote or Statutory Item | Truncated Vote or Statutory Wording | 2007-2008 Main Estimates |
2006-2007 Main Estimates |
| 1 |
Operating expenditures |
1,691.0 | 1,674.4 |
| 5 |
Grants and contributions |
1,225.9 | 1,189.4 |
|
(S) |
Minister of Health - Salary and motor car allowance |
0.1 | 0.1 |
|
(S) |
Contributions to employee benefit plans |
111.3 | 111.5 |
|
Total Department |
3,028.3 | 2,975.4 | |
|
The difference between the 2007-2008 Main Estimates and the 2006-2007 Main Estimates is due to various increases and decreases to the reference levels, of which some of the major increases are related to: the Special Meeting of the First Ministers and Aboriginal Leaders, the Canadian Strategy for Cancer Control, Chemical Management Plan, the
Implementation of the Clean Air Regulatory Agenda, and the yearly growth of the Indian Envelope. |
|||
Table 3
| Services Received Without Charge | |
|---|---|
| ($ millions) | 2007-2008 |
| Accommodation provided by Public Works and Government Services Canada (PWGSC) | 35.2 |
| Contributions covering employers' share of employees' insurance premiums and expenditures paid by the Treasury Board of Canada Secretariat | 42.3 |
| Workers' Compensation coverage provided by Human Resources and Skills Development Canada | 0.8 |
| Salary and associated expenditures of legal services provided by the Department of Justice Canada | 3.3 |
| 2007-2008 Services received without charge | 81.6 |
Table 4
| Sources of Respendable and Non-Respendable Revenues | ||||
|---|---|---|---|---|
| Respendable Revenues (millions of dollars) | ||||
| Program Activity | Forecast Revenue 2006-2007 |
Planned Revenue 2007-2008 |
Planned Revenue 2008-2009 |
Planned Revenue 2009-2010 |
| Health Products and Food | 38.8 | 41.2 | 41.2 | 41.2 |
| Healthy Environments and Consumer Safety | 12.0 | 15.7 | 16.0 | 16.0 |
| Pest Control Product Regulation | 7.0 | 7.0 | 7.0 | 7.0 |
| First Nations and Inuit Health | 3.7 | 5.4 | 5.4 | 5.4 |
| Total Respendable Revenues | 61.5 | 69.3 | 69.6 | 69.6 |
| Non-Respendable Revenues (millions of dollars) | ||||
| Program Activity | Forecast Revenue 2006-2007 |
Planned Revenue 2007-2008 |
Planned Revenue 2008-2009 |
Planned Revenue 2009-2010 |
| Health Products and Food | 3.9 | 3.9 | 3.9 | 3.9 |
| Healthy Environments and Consumer Safety | 1.7 | 1.7 | 1.7 | 1.7 |
| Pest Control Product Regulation | 1.0 | 1.0 | 1.0 | 1.0 |
| First Nations and Inuit Health | 2.3 | 2.3 | 2.3 | 2.3 |
| Total Non-Respendable Revenues | 8.9 | 8.9 | 8.9 | 8.9 |
| Total Respendable and Non-Respendable Revenues | 70.4 | 78.2 | 78.5 | 78.5 |
Table 5
| Resource Requirements by Branch and by Program Activity FOr 2007-2008 (in millions of dollars) | ||||||
|---|---|---|---|---|---|---|
| ($ millions) | Health Policy, Planning and Information | Health Products and Food | Healthy Environments and Consumer Safety | Pest Control Product Regulation | First Nations and Inuit Health | Total Planned Spending |
| Health Policy Branch | 247.7 | 247.7 | ||||
| Health Products and Food Branch | 203.0 | 203.0 | ||||
| Healthy Environments and Consumer Safety Branch | 276.4 | 276.4 | ||||
| Pest Management Regulatory Agency | 40.2 | 40.2 | ||||
| First Nations and Inuit Health Branch | 2,016.7 | 2,016.7 | ||||
| Chief Financial Officer Branch | 2.9 | 9.1 | 10.0 | 1.9 | 16.3 | 40.2 |
| Corporate Services Branch | 7.2 | 24.9 | 26.0 | 4.8 | 41.7 | 104.6 |
| Executive Offices* | 1.4 | 4.8 | 5.1 | 1.0 | 12.9 | 25.2 |
| Public Affairs, Consultation and Regions Branch** | 4.5 | 15.6 | 16.3 | 3.0 | 43.3 | 82.7 |
| Total | 263.7 | 257.4 | 333.8 | 50.9 | 2,130.9 | 3,036.7 |
| NOTE: * Includes such areas as Legal Services, Office of the Chief Scientist and Executive Offices. ** Includes such areas as Communications and Offices of Regional Directors General. |
||||||
Table 6
| Regulatory Plan | |
|---|---|
| Regulations | Expected Results |
| Program Activity: Health Policy, Planning and Information | |
| Regulations under the Assisted Human Reproduction Act (Section 8, Consent Regulations) |
These regulations will bring into force the section 8 prohibition of the Assisted Human Reproduction Act (AHR Act). They will ensure that all persons using human reproductive material to create an in vitro embryo or using an in vitro embryo for any purpose will obtain the written consent of the donor. |
| Regulations under the Assisted Human Reproduction Act (Subsection 14(2)b), Counselling Regulations) |
The AHR Act requires that before donating human reproductive material or in vitro embryos, donors receive counselling. The regulations will provide the details respecting these counselling services, such as who can provide the counselling. |
| Regulations under the Assisted Human Reproduction Act (Licensing Regulations) |
The AHR Act requires that all persons undertaking controlled activities (i.e., assisted human reproduction procedure such as in vitro fertilization) under the Act must obtain a license to undertake those activities. The AHR regulations will detail the requirements for obtaining that license such as the qualifications, premises and administrative requirements. |
| Regulations under the Assisted Human Reproduction Act (Section 10, Regulations for Clinical and Laboratory Activities) |
Section 10 of the AHR Act specifies that controlled activities must be performed in accordance with a license and regulations. The regulations with respect to controlled activities will define the conduct of core activities involved in the practice of assisted human reproduction (e.g., in vitro fertilization, embryo transfer). This initiative will address ethical, social, health and safety issues related to the conduct of these activities. |
| Regulations under the Assisted Human Reproduction Act (Record Keeping and Health Reporting Information Regulations for Controlled Activities) |
These regulations will specify what health reporting information Assisted Human Reproduction (AHR) clinics will need to collect for each AHR procedure that is performed. These regulations will also address retention, use, disclosure and destruction of health reporting information. |
| Regulations under the Assisted Human Reproduction Act (Section 12, Reimbursement of Expenditures) |
Section 12 of the AHR Act allows for the reimbursement of expenditures to donors of human reproductive material (i.e., semen, oocytes) and surrogate mothers. These AHR regulations will specify the reasonable expenditures that can be reimbursed. |
| Program Activity: Health Products and Food | |
| Food and Drug Act Safety of Human Cells, Tissues and Organs for Transplantation Regulations |
The purpose of this initiative is to minimize the potential health risks to Canadian recipients of human cells, tissues and organs (CTO). The proposed CTO regulations will address safety in the processing and handling of these products, resulting in improved protection of the health and safety of Canadian transplant recipients. |
| Food and Drug Regulations (Amendments to Division 3 with respect to Positron Emitting Radiopharmaceuticals) |
The purpose of this initiative is to amend Division 3, Part C of the Food and Drug Regulations with respect to the use of positron-emitting radiopharmaceuticals (PERs) in basic clinical research, in recognition of the fact that the application of the current regulations for clinical trials under Division 5, Part C of the FDR to PERs basic clinical research studies is placing an undue regulatory burden on the researchers in this field and may be impeding basic clinical research involving PERs in Canada. |
| Food and Drug Regulations (Safety of Blood and Blood Components Regulations) |
The purpose of this initiative is to replace the current requirements governing human blood and blood components in the Food and Drug Regulations with new comprehensive safety and quality of blood and blood components regulations. The objectives of the new regulations include: outlining clear and intelligible requirements; allowing for timely updating of the requirements as new technologies/products/issues emerge; and achieving greater harmonization in Canada related to the collection, handling and post-approval surveillance of blood and blood components. |
| Food and Drug Regulations (Extraordinary Use of New Drug Regulations) |
Under the Food and Drug Regulations a drug is approved only if substantial evidence of its efficacy is available. The purpose of this initiative is to amend the Food and Drug Regulations to allow for the approval of certain drugs the efficacy of which cannot be tested on humans in clinical trials for ethical reasons. These drugs may be required in emergency situations such as the treatment of pandemic influenza virus. The availability of these drugs is necessary to meet emergency preparedness measures which require the stockpiling of some of these drugs. |
| Food and Drug Regulations (Addition of Vitamins and Minerals to Foods) |
Facilitation of greater consumer choice and industry innovation by revision of regulations on the addition of vitamins and mineral nutrients to foods taking into account the role of nutrient addition to foods, consumer needs and expectations, and industry requests. |
| Food and Drug Regulations (Enhanced Food Labelling) |
Enhanced protection of allergic consumers through mandatory labelling of specific food allergens, gluten sources and sulphites when present at 10 parts per million or more, on the labels of prepackaged food products, whether they have been added directly or indirectly. |
| Food and Drug Regulations (Mandatory Labelling of Raw Ground Meat and Ground Poultry) |
Reduction of food borne illness as a result of providing safe handling information on the labels of these products which, due to their raw state, can introduce disease-causing bacteria to the food preparation environment. |
| Food and Drug Regulations (Health Claims) |
Addition of two diet-related health claims to the list of claims manufacturers can use to promote healthy foods regarding: fruits, vegetables and whole grains and reduced risk of heart disease; and folic acid and reduced risk of neural tube defects. |
| Food and Drug Regulations (Revisions to Division 12 - Prepackaged Water and Ice) |
Revision and updating of the safety and labelling requirements for prepackaged water and ice products. |
| Food and Drug Regulations (Amendments to Division 3 with respect to Positron Emitting Radiopharmaceuticals) |
The purpose of this initiative is to amend Division 3, Part C of the Food and Drug Regulations with respect to the use of positron-emitting radiopharmaceuticals (PERs) in basic clinical research, in recognition of the fact that the application of the current regulations for clinical trials under Division 5, Part C of the FDR to PERs basic clinical research studies is placing an undue regulatory burden on the researchers in this field and may be impeding basic clinical research involving PERs in Canada. |
| Food and Drug Regulations (Safety of Blood and Blood Components Regulations) |
The purpose of this initiative is to replace the current requirements governing human blood and blood components in the Food and Drug Regulations with new comprehensive safety and quality of blood and blood components regulations. The objectives of the new regulations include: outlining clear and intelligible requirements; allowing for timely updating of the requirements as new technologies/products/issues emerge; and achieving greater harmonization in Canada related to the collection, handling and post-approval surveillance of blood and blood components. |
| Food and Drug Regulations (Extraordinary Use of New Drug Regulations) |
Under the Food and Drug Regulations a drug is approved only if substantial evidence of its efficacy is available. The purpose of this initiative is to amend the Food and Drug Regulations to allow for the approval of certain drugs the efficacy of which cannot be tested on humans in clinical trials for ethical reasons. These drugs may be required in emergency situations such as the treatment of pandemic influenza virus. The availability of these drugs is necessary to meet emergency preparedness measures which require the stockpiling of some of these drugs. |
| Food and Drug Regulations (Addition of Vitamins and Minerals to Foods) |
Facilitation of greater consumer choice and industry innovation by revision of regulations on the addition of vitamins and mineral nutrients to foods taking into account the role of nutrient addition to foods, consumer needs and expectations, and industry requests. |
| Food and Drug Regulations (Enhanced Food Labelling) |
Enhanced protection of allergic consumers through mandatory labelling of specific food allergens, gluten sources and sulphites when present at 10 parts per million or more, on the labels of prepackaged food products, whether they have been added directly or indirectly. |
| Food and Drug Regulations (Mandatory Labelling of Raw Ground Meat and Ground Poultry) |
Reduction of food borne illness as a result of providing safe handling information on the labels of these products which, due to their raw state, can introduce disease-causing bacteria to the food preparation environment. |
| Food and Drug Regulations (Health Claims) |
Addition of two diet-related health claims to the list of claims manufacturers can use to promote healthy foods regarding: fruits, vegetables and whole grains and reduced risk of heart disease; and folic acid and reduced risk of neural tube defects. |
| Food and Drug Regulations (Revisions to Division 12 - Prepackaged Water and Ice) |
Revision and updating of the safety and labelling requirements for prepackaged water and ice products. |
| Amendments to the Natural Health Products Regulations, the Food and Drug Regulations and the Establishment Licensing Fees Regulations | The purpose of the proposed dual licensing regulatory amendment is to alleviate the exporting challenges arising from the coming into force of the Natural Health Products Regulations (NHPR). It will allow, on a voluntary basis, natural health product (NHP) companies to hold an establishment license (EL) pursuant to the
Food and Drug Regulations (FDR), in addition to the required site license under the NHPR. It is necessary for certain NHP companies to hold an EL, the license issued for pharmaceutical drugs, and obtain the accompanying export certificates in order to export their NHPs to countries that classify the NHPs in question as drugs. The proposed amendment consists of a two part regulatory package intended to come into force at the same time: 1) amendments to the NHPR/FDR, authorized under section 30 of the Food and Drugs Act; and 2) amendments to the Establishment Licensing Fees Regulations authorized under section 19.1(a) of the Financial Administration Act. |
| Medical Devices Regulations (Investigational Testing, Project 1467) |
Amendment to the Medical Devices Regulations to further address risks to health associated with investigational testing by requiring conformance to Good Clinical Practices, reporting to Health Canada for reviewing/monitoring, and introducing an inspection program. Proposed publication in the Canada Gazette, Part I in 2007-2008. |
| Food and Drug Regulations (Regulations amending the Special Access Program) |
The regulations that provide for emergency access to drugs that do not have a Canadian market authorization on a patient-basis. Amendments to the regulations will allow for the block release of such drugs to a population and/or for drug stockpiling to address public health emergencies. Proposed publication in the Canada Gazette, Part I in2007-2008. |
| Food and Drug Regulations (Regulations amending Division 1 requirements for Non-Medicinal Ingredients (NMI) in Drug Product Formulation) |
The proposed amendment would require the submission of complete qualitative and quantitative formulation data, including a list of all NMIs in a drug product, as well as the source of any human or animal derived NMIs or medicinal ingredients products currently regulated under Division 1 of the Regulations. Proposed publication in the Canada Gazette, Part I in 2007-2008. |
| Food and Drug Regulations (NMI Labelling, Project 743) |
The proposed amendment would require that all NMIs be listed on the outer labels of non-prescription drugs for human use. This would not apply to prescription drugs, low-level disinfectant drugs, or drugs for veterinary use. Proposed publication in the Canada Gazette, Part II in 2007-2008. |
| Food and Drug Regulations (Regulations amending Divisions 1 and 8, Progressive Licensing Project) |
A new regulatory framework that is based on sound science and risk management is being developed, including revised requirements for initial licensing of new products, provisions allowing for conditions of licensing (e.g., post-market commitments), regulations for the content and revisions of product monographs, provisions for continual evaluation and re-evaluation of licenses, new enforcement and compliance tools, regulations for the issuance of risk communication tools, and provisions for public involvement in the regulatory process. Proposed publication in the Canada Gazette, Part I in 2007-2008. |
| Food and Drug Regulations (Prohibition of Importation for Personal Use) |
Further restrict the importation of drugs to include the personal importation of drugs intended to be used in food-producing animals to avoid potentially harmful residues in food products from animals treated with these drugs. These regulatory amendments will better address the health risks to human and animal health and the safety of Canada's food supply associated with the use of unauthorized veterinary drugs. The proposed regulatory amendments will be published in Canada Gazette, Part I in 2007-2008 |
| Program Activity: Healthy Environments and Consumer Safety | |
| Marihuana Medical Access Regulations (Amendments to Part 2 and Part 3 of the Regulations) |
The purpose of these amendments is to ensure that the Marihuana Medical Access Regulations (MMAR) reflect the strategic direction of the medical marihuana access program. In particular, these amendments will focus on Part 2 (License To Produce) and Part 3 (General Obligations, including criteria for revocation) of the MMAR and
will address issues raised by both internal and external stakeholders subsequent to previous amendments made in June 2005. Amongst others, some of these issues are related to the maximum dosage (daily amount) and/or number of plants allowed to be grown by a person who is authorized to do so under the MMAR, strengthening the tools for compliance and enforcement, and reviewing the powers of inspectors. |
| Controlled Drugs and Substances Act (Amendment to Schedule Tramadol under this Act) |
The purpose of this amendment is to mitigate the risk of diversion associated with this substance, which has been shown to have abuse liability and dependence potential. This amendment will add the substance tramadol to Schedule I to the Controlled Drugs and Substances Act (CDSA), and regulate it under the Schedule to the Narcotic Control Regulations (NCR). Scheduling tramadol under the CDSA will impose greater controls and therefore minimize the risk of diversion and better mitigate public health risks. |
| Controlled Drugs and Substances Act (CDSA) (Regulations to Expand the Authority for Regulated Health Professionals to Prescribe Controlled Substances where Appropriate) |
The purpose of these regulations is to establish the conditions under which additional classes of health professionals (other than dentists, doctors of medicine and veterinary medicine) can be considered "practitioners" under the CDSA, and can therefore be granted authorities to conduct activities with certain controlled substances. The regulations are intended to contribute to improvements in the quality and efficiency of health care delivery to Canadians, and to keep pace with changes in the health care system in Canada (e.g., provincial/territorial ministries of Health are starting to allow a wider array of health professionals to prescribe drugs.) Achievement will be measured by improved alignment of federal and provincial/territorial regulatory frameworks governing the appropriate use of controlled substances for medical purposes. |
| Tobacco Advertising Regulations | Increased awareness of tobacco-related health hazards through mandating of new health warnings in advertising. Awareness will be measured through surveys. |
| Tobacco Regulations (Amendments regarding "Light" and "Mild" Descriptors) |
Reduced confusion among smokers regarding the "Light" and "Mild" descriptors. Greater awareness that no class of cigarettes is a "safer" alternative. Achievements will be measured through surveys. |
| Corded Window Coverings Regulations | Reduced risks to children's health (strangulation) posed by cords on window covering products such as mini-blinds and curtains. |
| Amending Cribs and Cradles Regulations | Reduced risks of injury to children posed by cribs, cradles and bassinets. |
| Regulations on Consumer Products Containing Lead (Group 1) (Products Intended to Be or Likely to Be Placed in the Mouth) |
Reduced health risks to children related to lead exposure. Examples include toys intended for children under 3 years of age, and mouthpieces used in sports equipment and musical instruments. Performance will be based on the removal of such hazardous products from the Canadian marketplace and the level of public awareness. |
| Regulations on Consumer Products Containing Lead (Group 2) (Products Intended for Use by Child or by an Adult Caring for a Child) |
Reduced health risks to children related to lead exposure. Examples include play equipment, strollers and children's clothing and accessories. Performance will be based on the removal of such hazardous products from the Canadian marketplace and the level of public awareness. |
| Program Activity: Pest Control Products Regulation | |
| Pest Control Products Act (New Regulations on Review Panels) |
The new Pest Control Products Act provides a process for the reconsideration of pesticide registration decisions whereby any person may file a notice of objection within sixty days of these decisions. Regulations will be made in 2007 to elaborate administrative matters concerning the process so as to make the timely resolution of reconsideration questions predictable and transparent. |